Every 8-K that Oaktree Acquisition Corp. III Life Sciences (OACC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OACC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OACC filings page.
Oaktree Acquisition Corp. III Life Sciences (OACC) shareholders approved an amendment extending the deadline to complete a business combination from October 25, 2026, to November 25, 2026. If requested by the sponsor, OAC may extend the deadline monthly without another shareholder vote, for an aggregate extension period of up to seven months after the original deadline, ending no later than May 25, 2027, unless a business combination closes earlier.
At the October 23, 2026 meeting, the extension proposal received 17,956,072 votes for and 802,517 against, with no abstentions. Holders representing approximately 76.3% of voting power as of September 22, 2026, were present. In connection with the vote, holders redeemed 11,331,102 public shares for approximately $122,435,287, at approximately $10.805 per share. Separately, sponsor Oaktree Acquisition Holdings III LS, LLC converted 4,798,758 Class B ordinary shares into Class A shares. After conversion, the sponsor held 5,382,739 Class A shares, including 583,981 private placement shares, and 1,000 Class B shares.
Oaktree Acquisition Corp. III Life Sciences (OACC) postponed its extraordinary general meeting from October 16, 2026, to October 23, 2026, at 10:00 a.m. Eastern Time, to permit further proxy solicitation and voting. Shareholders will consider a proposal to extend the date by which the company must complete an initial business combination.
The September 22, 2026 record date remains unchanged. Previously submitted proxies remain valid unless properly revoked. Shareholders may attend online; in-person attendance requires a reservation by October 21, 2026, at 10:00 a.m. Eastern Time.
Oaktree Acquisition Corp. III Life Sciences (OACC) reported that holders tendered 13,326,977 Class A ordinary shares for redemption by the October 14, 2026 deadline in connection with its proposed extension of the time to complete an initial business combination. The extension proposal is scheduled for an October 16, 2026 shareholder meeting. Assuming those redemptions and the conversion described below, OAC would have 11,254,791 Class A ordinary shares and 1,000 Class B ordinary shares issued and outstanding. Shareholders may request redemption withdrawals through Continental Stock Transfer & Trust Company.
Before the extension becomes effective, Sponsor Oaktree Acquisition Holdings III LS, LLC intends to convert 4,798,758 Class B shares into the same number of Class A shares on a one-for-one basis. The converted shares would be Founder Shares, subject to the same restrictions as the former Class B shares, including transfer restrictions and an obligation to vote in favor of a Business Combination. They would not be redeemable, and the Sponsor waived the right to receive Trust Account funds for them. The conversion would not change the Sponsor’s voting power.
Oaktree Acquisition Corp. III Life Sciences (OACC) reported a leadership change. On October 29, 2025, Chief Financial Officer Thomas Sweeney resigned, and the Board appointed George A. Martinez as CFO (principal accounting and principal financial officer), effective immediately. The company stated Mr. Sweeney’s resignation was not due to disagreements with the Board or management.
Mr. Martinez is a Senior Vice President in Oaktree’s finance organization and a Certified Public Accountant. He previously served as an Audit Senior Manager at Ernst & Young from 2013 to 2024. He will not be compensated by the Company for his CFO role and has no employment agreement. He is expected to enter into standard indemnity and letter agreements on the same terms as other directors and officers. No related‑party transactions or family relationships were disclosed.
Oaktree Acquisition Corp. III Life Sciences (OACC) appointed David A. Berry, MD, PhD as an independent director effective October 17, 2025. He will serve as a Class II director and join the audit, nominating, and compensation committees. The Board determined he meets independence standards under Nasdaq and Rule 10A-3.
Dr. Berry will not receive director compensation. Consistent with disclosures in the company’s 10-K, he is expected to have an opportunity to make a non‑controlling minority investment in Oaktree Acquisition Holdings III LS, LLC, and to enter standard Letter and Indemnity Agreements used for other directors and officers. No related-party transactions or family relationships were disclosed.